Stocks and Investing
Stocks and Investing
Mon, July 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew O"Brien Downgraded (ZBH) to Hold and Decreased Target to $115 on, Jul 1st, 2024
Matthew O"Brien of Piper Sandler, Downgraded "Zimmer Biomet Holdings, Inc." (ZBH) to Hold and Decreased Target from $140 to $115 on, Jul 1st, 2024.
Matthew has made no other calls on ZBH in the last 4 months.
There are 8 other peers that have a rating on ZBH. Out of the 8 peers that are also analyzing ZBH, 5 agree with Matthew"s Rating of Hold. Following are those relevant analyst calls for the last 4 months;
Mike Matson of "Needham" Reiterated at Hold on, Thursday, May 30th, 2024 David Roman of "Goldman Sachs" Initiated at Hold and Held Target at $129 on, Thursday, May 30th, 2024 Richard Newitter of "Truist Securities" Maintained at Hold with Decreased Target to $130 on, Friday, May 3rd, 2024 Vijay Kumar of "Evercore ISI Group" Maintained at Hold with Increased Target to $130 on, Thursday, April 4th, 2024 Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $140 on, Wednesday, April 3rd, 2024
These are the ratings of the 3 analyists that currently disagree with Matthew;
Matt Miksic of "Barclays" Maintained at Sell with Decreased Target to $125 on, Friday, May 31st, 2024 David Toung of "Argus Research" Upgraded from Hold to Strong Buy and Held Target at $150 on, Tuesday, May 21st, 2024 Steven Lichtman of "Oppenheimer" Maintained at Buy with Increased Target to $155 on, Friday, May 3rd, 2024
Contributing Sources